Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.55 |
| ▸ | NPC1 | O15118 | 7/20 | 0.55 |
| ▸ | RAB9A | P51151 | 7/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.50 |
| ▸ | RELA | Q04206 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12647464 | 0.87 | KDM4E (0.51) | KDM4ENPC1RAB9AALDH1A1HSD17B10 | |
| SCHEMBL23030044 | 0.85 | KDM4E (0.50) | KDM4ENPC1RAB9AALDH1A1HSD17B10 | |
| SCHEMBL14669947 | 0.83 | SMN1; SMN2 (0.50) | KDM4ENPC1RAB9AALDH1A1HSD17B10 | |
| SCHEMBL12664122 | 0.83 | KDM4E (0.48) | KDM4ENPC1RAB9AALDH1A1HSD17B10 | |
| SCHEMBL3305733 | 0.81 | PTGS1 (0.56) | RXFP1KDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL3368796 | 0.81 | NPC1 (0.63) | KDM4ENPC1RAB9AALDH1A1HSD17B10 | |
| SCHEMBL2505187 | 0.81 | PTGS1 (0.51) | RXFP1KDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL102433 | 0.80 | KDM4E (0.59) | KDM4ENPC1RAB9AALDH1A1HSD17B10 | |
| SCHEMBL7267686 | 0.80 | RXFP1 (0.53) | RXFP1KDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL19660422 | 0.80 | PTGS1 (0.54) | RXFP1KDM4ENPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-09-19 | — | — | US | disclosed |
| CN-112204009-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-3452456-B1 | BICYCLIC MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-109641854-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2023-02-03 | — | — | CN | disclosed |
| EP-4019521-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | Blueray Therapeutics (Shanghai) Co., Ltd (CN) | 2022-06-29 | — | — | EP | disclosed |
| US-11370758-B2 | IDO-TDO dual inhibitor and related methods of use | CMG PHARMACEUTICAL CO., LTD. (KR) | 2022-06-28 | — | — | US | disclosed |
| US-11370758-B2 | IDO-TDO dual inhibitor and related methods of use | CMG PHARMACEUTICAL CO., LTD. (KR) | 2022-06-28 | — | — | US | disclosed |
| US-20220106281-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2022-04-07 | — | — | US | disclosed |
| EP-3464286-B1 | PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20120225900-A1 | N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120165322-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
| US-20120165322-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
| WO-2012006203-A1 | N-CYCLYL-3 - (CYCLYLCARBONYLAMINOMETHYL) BENZAMIDE DERIVATIVES AS RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
| WO-2011058473-A1 | N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011058474-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20110111046-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | PFIZER INC | 2011-05-12 | — | — | US | disclosed |
| US-7704989-B2 | Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2010-04-27 | — | — | US | disclosed |
| US-20090149441-A1 | DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2009-06-11 | — | — | US | disclosed |
| EP-1831198-B1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110111046-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | ACACA, PC, ACACB | RXFP1 2316/4885KDM4E 1385/4885NPC1 271/4885 |
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | RXFP1 2368/4885KDM4E 4646/4885NPC1 1252/4885 |
| US-11370758-B2 | IDO-TDO dual inhibitor and related methods of use | IDO1, IDO2, TDO2 | RXFP1 893/4885KDM4E 910/4885NPC1 2627/4885 |
| US-20090149441-A1 | DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | NR4A2, NR4A3, NCOR1 | RXFP1 225/4885KDM4E 2303/4885NPC1 1018/4885 |
| US-20220106281-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | RXFP1 2368/4885KDM4E 4646/4885NPC1 1252/4885 |
| US-20120165322-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, RHOA | RXFP1 787/4885KDM4E 2031/4885NPC1 600/4885 |
| US-20120225900-A1 | N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, PC, ACACB | RXFP1 2446/4885KDM4E 1533/4885NPC1 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.